Article

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy

2025-11-13

Abstract excerpt

Gliomas account for ~80% of primary malignant brain tumors. Many CNS WHO grade 2–3 and some grade 4 gliomas harbor mutant isocitrate dehydrogenase 1 (mIDH1), which causes a gain of function mutation (IDH1 R132H) leading to the production of 2-hydroxyglutarate (2HG). Mutant IDH1-induced 2HG, through epigenetic reprogramming elicits an immune-permissive tumor microenvironment (TME). An immunosuppressive mechanism in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d4f42ef9-2043-50ed-b69b-ad25f51442e4
DOI: 10.1101/2025.11.11.687828

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene TherapyDOI 10.1101/2025.11.11.687828Read

Impact of epigenetic reprogramming on antitumor immune responses in glioma.Semantic proximity Read

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Semantic proximity Read

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in miceSemantic proximity Read

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity Read

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read

Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas.Semantic proximity Read

Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Semantic proximity Read

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.Semantic proximity Read

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric GliomasSemantic proximity Read